Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Trevi Therapeutics, Inc.NASDAQ: TRVI
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses grows, but more slowly than its trailing trend
Q3 FY2026 other income / expenses of $3.02M rose 43.6% year over year, behind the +70.2% change in trailing-twelve-month other income / expenses. Sequentially, it rose 12.0% from the prior quarter. Over 3 fiscal years it compounded at +108.4% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +43.6% toward the trailing-twelve-month pace of +70.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 6.51M USD
- Year-over-year change
- +81.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.51M | +81.6% |
| FY2024 | 2024-12-31 | 3.58M | -25.8% |
| FY2023 | 2023-12-31 | 4.83M | +571.2% |
| FY2022 | 2022-12-31 | 719K | +148.4% |
| FY2021 | 2021-12-31 | (1.49M) | — |
Other Income / Expenses vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +70.2% is the 4th highest of 9, against a peer median of +4.6%.
- Over three fiscal years its annual growth of +108.4% compares with a peer median of +644.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $136.83M USD | +7393.3% | — | 124.6% | |
| LTM Sep 2026 | $26.16M USD | -20.1% | +49.8% | 2.2% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $15.2M USD | -2.5% | +644.5% | 457.5% |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $14.93M USD | +11.7% | — | 74.6% |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 12.95M SEK | +413.0% | — | 973.7% |
| LTM Sep 2026 | $9.3M USD | +70.2% | +108.4% | — | |
| LTM Mar 2026 | $3.71M USD | +156.9% | +827.3% | — | |
| LTM Mar 2026 | -$1.86M USD | -1250.0% | — | 2.7% | |
| LTM Jun 2026 | -$19.07M USD | -488.0% | — | 4.2% | |
| Peer median (excluding TRVI) | — | +4.6% | +644.5% | 74.6% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.98M | 19.83M | 23.68M | 39.38M | 33.48M |
| Selling, General & Admin | 9.49M | 10.07M | 10.24M | 12.15M | 15.85M |
| Operating Expenses | 32.48M | 29.91M | 33.92M | 51.52M | 49.33M |
| Depreciation & Amortization | 50K | 43K | 123K | 147K | 144K |
| EBITDA | (32.71M) | (27.98M) | (28.58M) | (47.79M) | (42.68M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (32.48M) | (29.91M) | (33.92M) | (51.52M) | (49.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 10K | 1.74M | 4.75M | 3.6M | 6.54M |
| Interest Expense | 1.2M | 780K | 391K | 4K | 0 |
| Other Income / Expenses | (1.49M) | 719K | 4.83M | 3.58M | 6.51M |
| Income Before Tax | (33.96M) | (29.19M) | (29.1M) | (47.94M) | (42.82M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (21K) | (36K) | (32K) | (30K) | (64K) |
| Net Income | (33.94M) | (29.15M) | (29.07M) | (47.91M) | (42.76M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.49) | (0.45) | (0.29) | (0.47) | (0.29) |
| EPS (Diluted) | (1.49) | (0.45) | (0.29) | (0.47) | (0.29) |
| Weighted Avg Shares | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M |
| Weighted Avg Shares (Diluted) | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.